1,076 results match your criteria Cardiology in review[Journal]


The Effects of Transcatheter Aortic Valve Replacement on Mitral Valve Function.

Cardiol Rev 2020 Jun 18. Epub 2020 Jun 18.

Department of Medicine New York Medical College/Westchester Medical Center, Valhalla, NY 10595.

The transcatheter aortic valve replacement (TAVR) procedure provides a way to treat severe aortic stenosis in the large population of patients who are not candidates for surgical aortic valve replacement (SAVR). Mitral regurgitation is often concomitant to aortic stenosis in these patients due to the high pressure of the left ventricle and long-term damage to the mitral valve. Due to the proximity of the aortic valve to the mitral valve, TAVR can impact the functional status of the mitral valve by affecting left ventricular outlet obstruction and the mitral valve annular shape. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000315DOI Listing

The Inflammatory Relationship between Hepatitis C Virus with Coronary and Carotid Atherosclerosis.

Cardiol Rev 2020 Jun 18. Epub 2020 Jun 18.

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Hepatitis C Virus (HCV), a global health concern, has been linked to various hepatic and extrahepatic deleterious manifestations. Several observational studies, have either supported the increased likelihood of coronary and carotid atherosclerosis after infection with hepatitis C virus, or refuted it. To date, there has been no clear consensus to support either train of thought, as randomized, controlled clinical trials have not been completed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000314DOI Listing

Loeffler's Endocarditis and Hypereosinophilic Syndrome.

Cardiol Rev 2020 Jun 9. Epub 2020 Jun 9.

The Heart and Vascular Institute, Henry Ford West Bloomfield Hospital, West Bloomfield MI.

Loeffler's endocarditis and hypereosinophilic syndromes are a unique group of infiltrative disorders characterized by hypereosinophilia and inflammatory thrombotic and ultimately fibrotic involvement of the heart, leading to multiple complications including valve involvement, thromboembolic phenomena and heart failure. Clinical recognition, comprehensive laboratory and multimodality imaging diagnostic workup, and early initiation of treatment have been shown to slow down the progression and promote remission. This review addresses a detailed analysis of Loeffler's endocarditis and hypereosinophilic syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000324DOI Listing

The Total Artificial Heart: Where Are We ??

Cardiol Rev 2020 Jun 1. Epub 2020 Jun 1.

Departments of Surgery and Medicine, Banner-University of Arizona, Phoenix, AZ.

The total artificial heart (TAH) is a device that replaces the failing ventricles. There have been numerous TAHs designed over the last few decades, but the one with the largest patient experience is the SynCardia TAH-t. The 50-mL and 70-mL sizes have been approved in the United States, Europe, and Canada as a bridge to transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000322DOI Listing

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?

Cardiol Rev 2020 Jul/Aug;28(4):213-216

Department of Pharmacy, Montefiore Medical Center, Bronx, NY.

When the coronavirus disease 2019 (COVID-19) wreaked an unprecedented havoc of an escalating number of deaths and hospitalization in the United States, clinicians were faced with a myriad of unanswered questions, one of the them being the implication of the renin-angiotensin-aldosterone system in patients with COVID-19. Animal data and human studies have shown that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the expression of ACE2. ACE2 is an enzyme found in the heart, kidney, gastrointestinal tract, and lung and is a coreceptor for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV2), the virus responsible for COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000319DOI Listing

Nitrosamine Impurities in Angiotensin Receptor Blockers.

Cardiol Rev 2020 May 25. Epub 2020 May 25.

University of New Mexico College of Pharmacy, Albuquerque, New Mexico.

Nitrosamines are known carcinogens which have been recently discovered in several angiotensin receptor blockers (ARBs). This led to the recall of valsartan in the United States in 2018, and afterwards, the recall of other ARBs as well as unrelated medications (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000323DOI Listing

The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 1.

Cardiol Rev 2020 Jul/Aug;28(4):161-162

From the Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000316DOI Listing

The Novel Coronavirus Disease (COVID-19) and Its Impact on Cardiovascular Disease.

Cardiol Rev 2020 Jul/Aug;28(4):163-176

Department of Medicine, Division of Cardiovascular Medicine NorthShore University HealthSystem, Evanston, IL.

The coronavirus disease 2019 (COVID-19) pandemic has placed a significant strain on healthcare providers. As the number of patients continue to surge, healthcare workers are now forced to find different approaches to practicing medicine that may affect patient care. In addition, COVID-19 has many cardiovascular complications that affect the clinical course of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000317DOI Listing

Acute Aortic Occlusion and its Sequelae: Metabolic, Pathologic Etiology and Management.

Cardiol Rev 2020 Apr 28. Epub 2020 Apr 28.

Division of Vascular Surgery, New York University/Winthrop Hospital, Mineola, NY 11501.

Acute occlusion of the abdominal aorta is a catastrophic occurrence that results in high risk of limb loss and death. The etiology has historically been either acute embolism obstructing the aortic bifurcation in 8-75% of patients, or thrombosis of existing aorta-iliac occlusive disease in 35-84% of patients. Other etiologies include thrombosis of either a previously-placed endograft or aortic graft or acute dissection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000313DOI Listing

Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature.

Cardiol Rev 2020 Apr 23. Epub 2020 Apr 23.

Graduate Program in Cardiology and Cardiovascular Sciences, School of Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brazil.

Atrial fibrillation (AF) is considered the most common sustained cardiac arrhythmia, and it is associated with a significant risk of adverse events, especially ischemic stroke. Oral anticoagulation is the cornerstone for stroke prevention in AF; for many years, only vitamin K antagonists were used for this purpose, with an absolute risk reduction >60% for. However, these agents have limitations, such as narrow therapeutic margins and drug-food and drug-drug interactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000312DOI Listing

Diuretic Resistance in Heart Failure.

Cardiol Rev 2020 Mar 19. Epub 2020 Mar 19.

Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.

Decompensated heart failure accounts for approximately one million hospitalizations in the United States annually, and this number is expected to increase significantly in the near future. Diuretics provide the initial management in most patients with fluid overload. However, the development of diuretic resistance remains a significant challenge in the treatment of heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000310DOI Listing

Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.

Cardiol Rev 2020 Jul/Aug;28(4):177-189

From the Department of Medicine, Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY.

Cardiovascular disease (CVD) is a major contributor to the morbidity and mortality associated with type 2 diabetes mellitus (T2DM). With T2DM growing in pandemic proportions, there will be profound healthcare implications of CVD in person with diabetes. The ideal drugs to improve outcomes in T2DM are those having antiglycemic efficacy in addition to cardiovascular (CV) safety, which has to be determined in appropriately designed CV outcome trials as mandated by regulatory agencies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000308DOI Listing

Stress (Takotsubo) Cardiomyopathy; A Review of its Pathophysiology, Manifestations, and Factors that Affect Prognosis.

Cardiol Rev 2020 Mar 19. Epub 2020 Mar 19.

University of Connecticut Health, Farmington, Ct.

Stress (Takotsubo) cardiomyopathy (SC) is becoming an increasingly recognized syndrome, previously underdiagnosed due to its similar presentation to acute coronary syndrome (ACS). With advancements in imaging and diagnostic tools, our ability to recognize, diagnose and subsequently manage SC has advanced as well. Multiple diagnostic criteria have been created for the diagnosis of SC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000309DOI Listing

Nonpharmacologic Treatment for Heart Failure: A Review of Implantable Carotid Baroreceptor Stimulators as a Therapeutic Option.

Cardiol Rev 2020 Mar 19. Epub 2020 Mar 19.

Department of Medicine, Division of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, NY.

There has been significant interest in research for the development of device-based therapy as a treatment option of heart failure (HF), whether it is with reduced or preserved ejection fraction. This is due to the high morbidity and mortality rate in patients with HF despite recent advances in pharmacologic treatment. Following the success of cardiac resynchronization therapy, baroreceptor activation therapy has emerged as another novel device-based treatment for HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000307DOI Listing
March 2020
2.407 Impact Factor

Cardiovascular Safety and Benefits of Non-Insulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus - Part 2.

Cardiol Rev 2020 Apr 4. Epub 2020 Apr 4.

Department of Medicine and Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.

Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with anti-glycemic efficacy, as well as cardiovascular safety that has to be determined in appropriately designed cardiovascular outcome trials as mandated by regulatory agencies. The more recent anti-hyperglycemic medications have shown promise with regards to cardiovascular disease (CVD) risk reduction in T2DM patients at a high cardiovascular risk. Sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are associated with better cardiovascular outcomes and mortality in T2DM patients than are dipeptidyl peptidase-4 inhibitors, leading to the Food and Drug Administration's approval of empagliflozin to reduce mortality, and of liraglutide to reduce CVD risk in high-risk T2DM patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000311DOI Listing

Diastolic Heart Failure: A Review of Current and Future Treatment Options.

Cardiol Rev 2020 Feb 21. Epub 2020 Feb 21.

Department of Medicine, Division of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, NY.

Heart failure with preserved ejection fraction (HFpEF), often referred to as diastolic heart failure, remains one of the more challenging forms of heart failure to treat. This is a condition in which patients may or may not have signs and symptoms of heart failure, and retain a left ventricular EF > 50%. The challenge to treating HFpEF is due to the paucity of clinical trials with specific therapies, and those that have been completed have yielded relatively neutral results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000303DOI Listing
February 2020

Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy.

Cardiol Rev 2020 May/Jun;28(3):156-160

Department of Pharmacy, University of New Mexico Hospitals, Albuquerque, NM.

Transthyretin (TTR) amyloid cardiomyopathy is a life-threatening condition in which amyloid fibrils accumulate in the heart, eventually leading to cardiac symptomatology and death. To date, treatment of this condition has been directed at symptom relief due to a lack of effective treatment options which target the cause of the disease. The discovery that amyloid deposition was a result of dissociation of the TTR protein structure allowed for the development of tafamidis, which acts by stabilizing the TTR tetramer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000306DOI Listing
February 2020

Proarrhythmic Manifestations of Neuromuscular Dystrophinopathies.

Cardiol Rev 2020 Feb 14. Epub 2020 Feb 14.

Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.

Muscular dystrophy has been an elusive term ever since it was first described in the 19 century. Introduced in 1891 by Wilhem Heinrich Erb, muscular dystrophy has been classified as part of a larger group of genetically-determined, progressive degenerative neuromuscular disorders termed "dystrophinopathies." Cardiac arrhythmias may occur during the neurologic course of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000305DOI Listing
February 2020

Treatment of Peripheral Pulmonary Artery Stenosis.

Cardiol Rev 2020 Feb 12. Epub 2020 Feb 12.

From the Department of Medicine, Cardiology Division, New York Medical College/ Westchester Medical Center, Valhalla, NY.

Peripheral pulmonary artery stenosis (PAS) is an abnormal narrowing of the pulmonary vasculature and can form anywhere within the pulmonary artery tree. PAS is a congenital or an acquired disease, and its severity depends on the etiology, location, and number of stenoses. Most often seen in infants and young children, some symptoms include shortness of breath, fatigue, and tachycardia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000300DOI Listing
February 2020

Heavy Metal Toxicity in Chronic Renal Failure and Cardiovascular Disease. Possible Role for Chelation Therapy.

Cardiol Rev 2020 Feb 6. Epub 2020 Feb 6.

From the Department of Medicine.

Exposure to heavy metals is common. This exposure is related to environmental contamination of air, water and soil, occupational exposure, accumulation in food, tobacco and other factors. Cadmium and lead are notable for their widespread contamination, long lasting effects in the body, and renal as well as cardiovascular toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000304DOI Listing
February 2020

Arrhythmogenic Right Ventricular Cardiomyopathy Diagnosis.

Cardiol Rev 2020 Feb 3. Epub 2020 Feb 3.

From the Department of Medicine, Cardiology Division, New York Medical College/ Westchester Medical Center, Valhalla, NY.

Arrhythmogenic right ventricular cardiomyopathy (ARVC), formerly called 'arrhythmogenic right ventricular dysplasia', is an under-recognized clinical entity characterized by ventricular arrhythmias and a characteristic ventricular pathology. Diagnosis is often difficult due to the nonspecific nature of the disease and the broad spectrum of phenotypic variations. Therefore, consensus diagnostic criteria have been developed which combine electrocardiographic, echocardiographic, cardiac magnetic resonance imaging and histologic criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000292DOI Listing
February 2020

Stem Cell Therapy for Acute Myocardial Infarctions: A Systematic Review.

Cardiol Rev 2020 May/Jun;28(3):140-147

Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY.

Each year 790,000 people in the United States suffer from a myocardial infarction. This results in the permanent loss of cardiomyocytes and an irreversible loss of cardiac function. Current therapies lower mortality rates, but do not address the core pathology, which opens a pathway to step-wise heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000291DOI Listing
February 2020

Myocardial Depression in Sepsis: Beneficial Adaptation or Sequelae that Requires Treatment?

Cardiol Rev 2020 Feb 3. Epub 2020 Feb 3.

New York Medical College/Westchester Medical Center, Valhalla, NY.

Myocardial depression is a common, yet reversible phenomenon that occurs in patients in septic shock. Initially, it was unclear whether this provided an adaptive survival benefit, as early studies showed decreased mortality in septic patients with myocardial depression. However, subsequent larger studies have debunked this myth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000301DOI Listing
February 2020

Pulmonary Artery Denervation as an Innovative Treatment for Pulmonary Hypertension with and without Heart Failure.

Cardiol Rev 2020 Feb 3. Epub 2020 Feb 3.

From the Department of Medicine, Cardiology Division, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.

Pulmonary hypertension (PH) is categorized into five groups based on etiology. The two most prevalent forms are pulmonary arterial hypertension (PAH) and PH due to left heart disease (PH-LHD). Therapeutic options do exist for PAH to decrease symptoms and improve functional capacity; however, the mortality rate remains high and clinical improvements are limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000299DOI Listing
February 2020

The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent.

Cardiol Rev 2020 Jul/Aug;28(4):208-212

From the Division of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.

Despite recent advances in drug-eluting stent (DES) technology, late adverse events remain concerns after percutaneous coronary intervention. The persistence of polymer material on DES has been suggested as a trigger for chronic inflammation. The Firehawk, a novel DES, has a unique design with recessed abluminal grooves, to which sirolimus and biodegradable polymer are applied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000298DOI Listing
February 2020

Machine Intelligence in Cardiovascular Medicine.

Authors:
D Douglas Miller

Cardiol Rev 2020 Mar/Apr;28(2):53-64

From the Department of Medicine, Radiology and Population Health Sciences, Medical College of Georgia, Augusta, GA.

The computer science technology trend called artificial intelligence (AI) is not new. Both machine learning and deep learning AI applications have recently begun to impact cardiovascular medicine. Scientists working in the AI domain have long recognized the importance of data quality and provenance to AI algorithm efficiency and accuracy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000294DOI Listing
February 2020

Peripartum Cardiomyopathy Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology, and Treatment Options.

Cardiol Rev 2020 May/Jun;28(3):148-155

From the Department of Medicine and Cardiology Division, Westchester Medical Center and New York Medical College, Valhalla, NY.

Peripartum cardiomyopathy is a rare and a severe form of heart failure that affects women during pregnancy or shortly after delivery. Risk factors include advanced age, race, multiparity, multifetal pregnancy, socioeconomic disparity, and medical comorbidities including systemic hypertension, diabetes, asthma, and anemia. Peripartum cardiomyopathy is associated with increased morbidity and mortality, as well as a detrimental long-term impact on quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000249DOI Listing
January 2020

Does Transcatheter Aortic Valve Implantation for Aortic Stenosis Impact on Cognitive Function?

Cardiol Rev 2020 May/Jun;28(3):135-139

Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

Aortic stenosis (AS) is the most common valvular heart disease among elderly patients in developed countries. Surgical valve replacement is indicated for severe AS to relieve the obstructed outflow tract. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative for patients with severe AS, particularly in those with high surgical risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000279DOI Listing
January 2020

Comprehensive Review of Cardiovascular Diseases, Diabetes, and Hypercholesterolemia in Lebanon.

Cardiol Rev 2020 Mar/Apr;28(2):73-83

Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

The Middle East and North Africa regions, including Lebanon, have recently witnessed rapid urbanization and modernization over the last couple of decades that has led to a dramatic transformation affecting lifestyle and diet. The World Health Organization reports that the leading cause of death in Lebanon is due to cardiovascular disease (CVD) at 47% of all-cause mortality. Over the last 30 years, especially the last 10, the population of Lebanon has changed dramatically due to the effect of wars in the region and refugees seeking asylum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000290DOI Listing
January 2020

A Practical Approach to Hybrid Coronary Revascularization.

Cardiol Rev 2020 Jan 23. Epub 2020 Jan 23.

Section of Cardiology, Department of Medicine, Tulane University School of Medicine; Tulane University Heart and Vascular Institute, New Orleans, Louisiana, US.

Combined surgical and percutaneous coronary revascularization i.e. hybrid coronary revascularization (HCR) consists of surgical left internal mammary artery (LIMA) bypass to the left anterior descending artery (LAD) and percutaneous revascularization of other diseased coronary arteries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000278DOI Listing
January 2020

Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After an Intracranial Hemorrhage.

Cardiol Rev 2020 Jul/Aug;28(4):190-196

Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY.

Atrial fibrillation is the most common sustained cardiac arrhythmia in the general population. In western countries with aging populations, atrial fibrillation poses a significant health concern, as it is associated with a high risk of thromboembolism, stroke, congestive heart failure, and myocardial infarction. Thrombi are generated in the left atrial appendage, and subsequent embolism into the cerebral circulation is a major cause of ischemic stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000288DOI Listing
January 2020

Biomarkers of Aortopathy in Marfan Syndrome.

Cardiol Rev 2020 Mar/Apr;28(2):92-97

Biomarker and Drug Analysis Core Facility, Medical Research Institute, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY, UK.

Marfan Syndrome (MFS) is an autosomal dominant, genetically inherited connective tissue disorder which primarily affects the cardiovascular system, but can also have systemic manifestations. First described in 1896, MFS has a prevalence of around 1/5000 in the general population. It is becoming increasingly common to see patients with MFS in a clinical setting due to the improved care of patients with adult congenital heart disease and general improvement in survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000289DOI Listing
January 2020
2.407 Impact Factor

Mineralocorticoid Receptor Antagonist Use in Heart Failure With Reduced Ejection Fraction and End-Stage Renal Disease Patients on Dialysis: A Literature Review.

Cardiol Rev 2020 May/Jun;28(3):107-115

From the Division of Cardiology, Department of Medicine, Westchester Medical Center/New York Medical College, Valhalla, NY.

Mineralocorticoid receptor antagonists (MRAs) are known to have a proven mortality benefit in heart failure with reduced ejection fraction (HFrEF) without kidney disease. As patients with end-stage renal disease (ESRD) requiring either peritoneal dialysis or hemodialysis were excluded in clinical trials of HFrEF, the data are scant on the appropriate use of MRAs in this population. The unknown efficacy, along with concerns of adverse effects such as hyperkalemia, has limited the willingness of clinicians to consider using MRAs in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000286DOI Listing
January 2020
2.407 Impact Factor

Towards a Saphenous Vein Graft Moratorium.

Cardiol Rev 2020 Jan 23. Epub 2020 Jan 23.

Division of Cardiology Department of Medicine Tulane University School of Medicine, New Orleans, Louisiana, US.

Atherosclerosis develops and rapidly progresses in saphenous veins grafts after coronary bypass surgery. In contrast to native coronary artery, percutaneous revascularization does not impede the progression of saphenous vein atherosclerosis and saphenous vein graft failure commonly ensues. The protracted patency of arterial grafts is likely to account for most of the long-term superiority of coronary artery bypass surgery over percutaneous revascularization in patients with complex coronary artery disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000277DOI Listing
January 2020

Timing of Repair in Tetralogy of Fallot: Effects on Outcomes and Myocardial Health.

Cardiol Rev 2020 Jan 2. Epub 2020 Jan 2.

From the Divisions of Cardiology, the Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Early complete repair of Tetralogy of Fallot (ToF) prior to 1 year of age has been demonstrated to be safe and has survival benefits over late repair. The age at repair of ToF affects long-term outcomes. This may largely be related to preserved, or comparatively better, myocardial health. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000293DOI Listing
January 2020

Catecholaminergic Polymorphic Ventricular Tachycardia.

Cardiol Rev 2020 Jan 2. Epub 2020 Jan 2.

From the Department of Medicine, Cardiology Division, New York Medical College and Westchester Medical Center, Valhalla, NY, USA.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare congenital arrhythmogenic disorder induced by physical or emotional stress. It mainly affects children and younger adults and is characterized by rapid polymorphic and bidirectional ventricular tachycardia. Symptoms can include dizziness, palpitations, and presyncope, which may progress to syncope, hypotonia, convulsive movements, and sudden cardiac death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000302DOI Listing
January 2020

Sarcopenia and Cardiac Dysfunction.

Cardiol Rev 2020 Jul/Aug;28(4):197-202

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Although muscle loss is part of the natural course of human aging, sarcopenia has been associated with an increased risk of physical disability and mortality in older patients. Many heart failure patients concomitantly develop deficits in muscle mass and strength, resulting in decreased quality of life and exercise capacity. An underlying state of inflammation is central to the development of sarcopenia and muscle wasting in heart failure; however, additional research in human models is needed to further delineate the pathophysiology of muscle wasting in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000285DOI Listing
December 2019

Severe Hypoglycemia and Risk of Subsequent Cardiovascular Events: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Cardiol Rev 2019 Dec 9. Epub 2019 Dec 9.

Intensive glycemic control significantly increases the risk of hypoglycemia in patients with diabetes mellitus. Recent data have shown that hypoglycemia may also be a marker of cardiovascular disease in these patients. We performed a systemic review and a meta-analysis to evaluate the relationship between severe hypoglycemic events (SHE) and the subsequent risk of mortality and major adverse cardiovascular events (MACE) in patients with diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000276DOI Listing
December 2019

Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials.

Cardiol Rev 2020 May/Jun;28(3):116-124

Division of Cardiology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY.

Diabetes mellitus (DM) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular morbidity and mortality. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a new class of hypoglycemic agents that have shown significant promise in the reduction of cardiovascular events. Current guideline recommendations do not support the use of these agents in patients with CKD stage 3 or higher. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000265DOI Listing
December 2019

Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management.

Cardiol Rev 2020 Mar/Apr;28(2):84-91

From the Division of Endocrinology, Department of Medicine, Westchester Medical Center at New York Medical College, Valhalla, NY.

Primary aldosteronism remains a leading cause of secondary hypertension, and its diagnosis and management continue to pose a challenge for clinicians. In this article, we review the diagnosis of primary aldosteronism along with its cardiovascular manifestations. Treatment is described depending on the diagnostic outcome, focusing on medical management with mineralocorticoid receptor antagonists and unilateral adrenalectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000281DOI Listing
December 2019

Right Heart Catheterization-Related Complications: A Review of the Literature and Best Practices.

Cardiol Rev 2020 Jan/Feb;28(1):36-41

From the Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.

Right heart catheterization (RHC) is considered to be the gold standard for the measurement of pulmonary artery pressure and has a class 1 indication to confirm the diagnosis of pulmonary arterial hypertension and to guide treatment decisions. Associated complications with RHC in contemporary practice are uncommon. In this review, we aim to summarize the complications that have been published in case reports or case series with updated management and techniques to prevent and mitigate complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000270DOI Listing
April 2020
2.407 Impact Factor

Care of the Post-CABG Patient.

Cardiol Rev 2020 Jan/Feb;28(1):26-35

Division of Cardiology, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA.

An estimated 400,000 coronary artery bypass graft operations are performed annually in the United States. Saphenous vein grafts are the most commonly used conduits; however, graft failure is common. In contrast, left internal mammary artery grafts have more favorable long-term patency rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000261DOI Listing

Beta Adrenergic Blocker Use in Patients With Chronic Obstructive Pulmonary Disease and Concurrent Chronic Heart Failure With a Low Ejection Fraction.

Cardiol Rev 2020 Jan/Feb;28(1):20-25

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD) often coexist and present clinicians with diagnostic and therapeutic challenges. Beta-blockers are a cornerstone of CHF treatment, in patients with a low ejection fraction, while beta-agonists are utilized for COPD. These 2 therapies exert opposing pharmacological effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000284DOI Listing

Cardiovascular Sequelae of Sickle Cell Disease.

Cardiol Rev 2020 Jan/Feb;28(1):10-13

From the Department of Medicine, Westchester Medical Center.

Sickle cell disease (SCD) is one of the most common hereditary hemoglobinopathies worldwide. It is a multisystem disease that causes considerable patient morbidity. Despite advances in medical treatment, cardiopulmonary complications remain the most common cause of death in individuals with SCD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000264DOI Listing

George Reed, MD: Cardiac Surgical Pioneer and Visionary.

Authors:
George L Hines

Cardiol Rev 2020 Jan/Feb;28(1):1-2

Department of Thoracic and Cardiovascular Surgery, New York University Winthrop Hospital, Mineola, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000287DOI Listing

Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction.

Cardiol Rev 2020 Mar/Apr;28(2):65-72

Medicine Service, Carl Vinson VA Medical Center, Dublin, GA.

Cardiovascular disorders, such as orthostatic hypotension and supine hypertension, are common in patients with neurodegenerative synucleinopathies such as Parkinson disease (PD), and may also occur in other conditions, such as peripheral neuropathies, that result in autonomic nervous system (ANS) dysfunction. Dysfunction and degeneration of the ANS are implicated in the development of orthostatic and postprandial hypotension and impaired thermoregulation. Neurogenic orthostatic hypotension (nOH) results from sympathetic failure and is a common autonomic disorder in PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000280DOI Listing
November 2019

Aspirin for the Primary Prevention of Cardiovascular Disease: A Review of the Literature and Considerations for Clinical Practice.

Cardiol Rev 2020 Mar/Apr;28(2):98-106

Division of Cardiology, Department of Medicine, University of North Carolina Hospitals, Chapel Hill, NC.

Cardiovascular disease is the leading cause of death globally, and deaths due to coronary heart disease or stroke account for over half of all cardiovascular deaths in the United States. While many important advances have been made in the treatment and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), morbidity and mortality remain high. Aspirin has been commonly used for the primary and secondary prevention of ASCVD for decades and is an easily accessible therapeutic option. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000297DOI Listing
November 2019

Functional Mitral Regurgitation in Heart Failure. Erratum.

Authors:

Cardiol Rev 2020 Jan/Feb;28(1):52

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000296DOI Listing
November 2019

Lipoprotein(a) Testing and Emerging Therapies.

Cardiol Rev 2019 Oct 30. Epub 2019 Oct 30.

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

The study of lipoprotein(a) [Lp(a)] over the years has been a source of both enlightenment and frustration for the medical community. Accumulating evidence from large sample observational studies, Mendelian randomization studies, and genome-wide association studies has strengthened the association between Lp(a) and the development of atherosclerotic cardiovascular disease. This evidence supports the testing of Lp(a) in certain high risk populations in order for clinicians to improve the risk profile of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000295DOI Listing
October 2019